Fragment-Based Approaches in Drug Discovery and Chemical Biology

被引:334
|
作者
Scott, Duncan E. [1 ]
Coyne, Anthony G. [1 ]
Hudson, Sean A. [1 ]
Abell, Chris [1 ]
机构
[1] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England
基金
英国惠康基金; 英国生物技术与生命科学研究理事会;
关键词
X-RAY CRYSTALLOGRAPHY; MULTITARGETED KINASE INHIBITOR; PROTEIN-PROTEIN INTERACTIONS; CRYSTAL-STRUCTURE; BETA-SECRETASE; LEAD DISCOVERY; DESIGN; NMR; BINDING; IDENTIFICATION;
D O I
10.1021/bi3005126
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fragment-based approaches to finding novel small molecules that bind to proteins are now firmly established in drug discovery and chemical biology. Initially developed primarily in a few centers in the biotech and pharma industry, this methodology has now been adopted widely in both the pharmaceutical industry and academia. After the initial success with kinase targets, the versatility of this approach has now expanded to a broad range of different protein classes. Herein we describe recent fragment-based approaches to a wide range of target types, including Hsp90, beta-secretase, and allosteric sites in human immunodeficiency virus protease and fanesyl pyrophosphate synthase. The role of fragment-based approaches in an academic research environment is also examined with an emphasis on neglected diseases such as tuberculosis. The development of a fragment library, the fragment screening process, and the subsequent fragment hit elaboration will be discussed using examples from the literature.
引用
收藏
页码:4990 / 5003
页数:14
相关论文
共 50 条
  • [41] Fragment-based drug discovery: From crystal to clinic
    Patel, Joe
    [J]. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2008, 64 : C37 - C37
  • [42] Introduction to the themed collection on fragment-based drug discovery
    Rees, David C.
    Hirsch, Anna K. H.
    Erlanson, Daniel A.
    [J]. RSC MEDICINAL CHEMISTRY, 2022, 13 (12): : 1439 - 1439
  • [43] Fragment-based drug discovery at adaptive protein sites
    Erlanson, Daniel A.
    [J]. FASEB JOURNAL, 2007, 21 (05): : A209 - A209
  • [44] Informatics and modeling challenges in fragment-based drug discovery
    Hubbard, Roderick E.
    Chen, Ijen
    Davis, Ben
    [J]. CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2007, 10 (03) : 289 - 297
  • [45] Native Mass Spectrometry in Fragment-Based Drug Discovery
    Pedro, Liliana
    Quinn, Ronald J.
    [J]. MOLECULES, 2016, 21 (08)
  • [46] Covalent fragment-based drug discovery for target tractability
    McCarthy, William J.
    van der Zouwen, Antonie J.
    Bush, Jacob T.
    Rittinger, Katrin
    [J]. CURRENT OPINION IN STRUCTURAL BIOLOGY, 2024, 86
  • [47] ACFIS: a web server for fragment-based drug discovery
    Hao, Ge-Fei
    Jiang, Wen
    Ye, Yuan-Nong
    Wu, Feng-Xu
    Zhu, Xiao-Lei
    Guo, Feng-Biao
    Yang, Guang-Fu
    [J]. NUCLEIC ACIDS RESEARCH, 2016, 44 (W1) : W550 - W556
  • [48] Fragment-based drug discovery: From crystal to clinic
    Howard, Steven
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 559 - 559
  • [49] Fragment-based drug discovery using NMR spectroscopy
    Harner, Mary J.
    Frank, Andreas O.
    Fesik, Stephen W.
    [J]. JOURNAL OF BIOMOLECULAR NMR, 2013, 56 (02) : 65 - 75
  • [50] USING COMPUTATIONAL TECHNIQUES IN FRAGMENT-BASED DRUG DISCOVERY
    DesJarlais, Renee L.
    [J]. FRAGMENT-BASED DRUG DESIGN: TOOLS, PRACTICAL APPROACHES, AND EXAMPLES, 2011, 493 : 137 - 155